Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3

British Journal of Pharmacology

Volumn 170, Issue 4, 2013, Pages 807-821

  Subramaniam, Aruljothi ^a,b   Shanmugam, Muthu K ^a   Ong, Tina H ^c   Li, Feng ^a   Perumal, Ekambaram ^b   Chen, Luxi ^a,d   Vali, Shireen ^e   Abbasi, Taher ^e   Kapoor, Shweta ^f   Ahn, Kwang Seok ^g   Kumar, Alan Prem ^a,d,h,i   Hui, Kam M ^c   Sethi, Gautam ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b BHARATHIAR UNIVERSITY   (India)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e CELLWORKS GROUP INC   (United States)

^f Systemantics India Pvt Ltd   (India)

^g Kyung Hee University   (South Korea)

^h CURTIN UNIVERSITY   (Australia)

ⁱ UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

apoptosis; emodin; hepatocellular carcinoma; proliferation; STAT3

Indexed keywords

EMODIN; JANUS KINASE 1; JANUS KINASE 2; PROTEIN KINASE; PROTEIN KINASE P60; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; SMALL INTERFERING RNA; STAT3 PROTEIN; VANADIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG EFFECT; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHP 1 GENE;

APOPTOSIS; EMODIN; HEPATOCELLULAR CARCINOMA; PROLIFERATION; STAT3;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EMODIN; FEMALE; HEP G2 CELLS; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; JANUS KINASE 2; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885105794     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12302     Document Type: Article

References (45)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
2. Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G, Pinna LA, (2000). The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem 275: 29618-29622.
3. Bromberg J, Wang TC, (2009). Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80.
4. Brown M, Bellon M, Nicot C, (2007). Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 109: 1653-1659.
5. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. (2006). Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130: 1117-1128.
6. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G, (2012). Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3: 236-260.
7. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML, (1999). Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem 274: 23013-23019.
8. Chen YC, Shen SC, Lee WR, Hsu FL, Lin HY, Ko CH, et al. (2002). Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 64: 1713-1724.
9. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, et al. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362.
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
11. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, et al. (2007). Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 363: 738-744.
12. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, et al. (2006). Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12: 11-19.
13. Grivennikov SI, Karin M, (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21: 11-19.
14. Han Y, Amin H, Franko B, Frantz C, Shi X, Lai R, (2006). Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Blood 108: 2796-2803.
15. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al. (2009). The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16: 487-497.
16. Huang Q, Shen HM, Ong CN, (2004). Inhibitory effect of emodin on tumor invasion through suppression of activator protein-1 and nuclear factor-kappaB. Biochem Pharmacol 68: 361-371.
17. Ihle JN, (1996). STATs: signal transducers and activators of transcription. Cell 84: 331-334.
18. Johnston PA, Grandis JR, (2011). STAT3 signaling: anticancer strategies and challenges. Mol Interv 11: 18-26.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
20. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. (2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15: 283-293.
21. Lin H, van den Esschert J, Liu C, van Gulik TM, (2011). Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol 26: 28-35.
22. Lin SY, Lai WW, Ho CC, Yu FS, Chen GW, Yang JS, et al. (2009). Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. Anticancer Res 29: 327-335.
23. Liu A, Chen H, Tong H, Ye S, Qiu M, Wang Z, et al. (2011). Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-kappaB. Mol Med Rep 4: 221-227.
24. Manu KA, Shanmugam MK, Ong TH, Subramaniam A, Siveen KS, Perumal E, et al. (2013). Emodin suppresses migration and invasion through the modulation of CXCR4 expression in an orthotopic model of human hepatocellular carcinoma. PLoS ONE 8: e57015.
25. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Meng G, Liu Y, Lou C, Yang H, (2010). Emodin suppresses lipopolysaccharide-induced pro-inflammatory responses and NF-kappaB activation by disrupting lipid rafts in CD14-negative endothelial cells. Br J Pharmacol 161: 1628-1644.
27. Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T, et al. (2007). Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 6: 987-994.
28. Newman DJ, (2008). Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 51: 2589-2599.
29. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. (2002). Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008.
30. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Vali S, et al. (2011). Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo. Clin Cancer Res 17: 1425-1439.
31. Rajendran P, Li F, Shanmugam MK, Kannaiyan R, Goh JN, Wong KF, et al. (2012). Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila) 5: 631-643.
32. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, Vali S, et al. (2010). Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol 65: 903-911.
33. Schreiner SJ, Schiavone AP, Smithgall TE, (2002). Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J Biol Chem 277: 45680-45687.
34. Seitz SJ, Schleithoff ES, Koch A, Schuster A, Teufel A, Staib F, et al. (2010). Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int J Cancer 126: 2049-2066.
35. Shieh DE, Chen YY, Yen MH, Chiang LC, Lin CC, (2004). Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci 74: 2279-2290.
36. Subramaniam A, Loo SY, Rajendran P, Manu KA, Perumal E, Li F, et al. (2013a). An anthraquinone derivative, emodin sensitizes hepatocellular carcinoma cells to TRAIL induced apoptosis through the induction of death receptors and downregulation of cell survival proteins. Apoptosis. (in press).
37. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, et al. (2013b). Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 1835: 46-60.
38. Tabolacci C, Lentini A, Mattioli P, Provenzano B, Oliverio S, Carlomosti F, et al. (2010). Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells. Life Sci 87: 316-324.
39. Tan SM, Li F, Rajendran P, Kumar AP, Hui KM, Sethi G, (2010). Identification of beta-escin as a novel inhibitor of signal transducer and activator of transcription 3/Janus-activated kinase 2 signaling pathway that suppresses proliferation and induces apoptosis in human hepatocellular carcinoma cells. J Pharmacol Exp Ther 334: 285-293.
40. Wang H, Lafdil F, Kong X, Gao B, (2011). Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci 7: 536-550.
41. Wang R, Wan Q, Zhang Y, Huang F, Yu K, Xu D, et al. (2007). Emodin suppresses interleukin-1beta induced mesangial cells proliferation and extracellular matrix production via inhibiting P38 MAPK. Life Sci 80: 2481-2488.
42. Wang SC, Zhang L, Hortobagyi GN, Hung MC, (2001). Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 28 (6 Suppl. 18): 21-29.
43. Wu C, Guan Q, Wang Y, Zhao ZJ, Zhou GW, (2003). SHP-1 suppresses cancer cell growth by promoting degradation of JAK kinases. J Cell Biochem 90: 1026-1037.
44. Xia QS, Sun RY, Xiu RJ, (2009). [Progress of research on molecular mechanisms in antitumor effect of emodin]. Zhongguo Zhong Xi Yi Jie He Za Zhi 29: 85-88.
45. Xu XC, Lin SZ, (2008). [Experimental advance of applying emodin for prevention and treatment of liver diseases]. Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 91-93.